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AbstrACt
Introduction Intrathoracic shunt quantification is a 
major factor for appropriate clinical management of 
heart and pulmonary diseases. Intracardiac shunts 
quantified by pulmonary to systemic output ratio (Qp/
Qs) are generally assessed by Doppler echocardiography, 
MRI or catheterisation. Recently, some authors have 
suggested the concomitant use of thoracic bioimpedance 
(TB) and inert gas rebreathing (IGR) techniques for shunt 
quantification. The purpose of this study is to validate the 
use of this approach under conditions where shunt fraction 
is directly quantified such as in patients with isolated atrial 
septal defect (ASD).
Methods and analysis This trial is a prospective, 
observational single-centre, non-blinded study of adults 
seen for percutaneous closure of ASD. Qp/Qs ratio will be 
directly measured by Doppler echocardiography and direct 
Fick. IGR and TB will be used simultaneously to measure 
the cardiac output before and after closure: the ratio of 
outputs measured by IGR and TB reflecting the shunt 
fraction. The primary outcome will be the comparison 
of shunt values measured by TB-IGR and Doppler 
echocardiography.
Ethics and dissemination The study has been approved 
by an independent Research Ethics Committee (2017-
A03149-44 Fr) and registered as an official clinical trial. 
The results will be published in a peer-reviewed journal.
trial registration number NCT03437148; Pre-results.
IntroduCtIon
Intrathoracic shunt quantification is a major 
parameter for the clinical management of 
cardiac and pulmonary diseases. Several tech-
niques are currently available for quantifica-
tion but present some limitations: the direct 
Fick method is invasive and therefore not 
first indication, easy access to MRI remains 
an issue in several clinical centres while the 
precision and repeatability of Doppler echo-
cardiography measurements is highly depen-
dent on technical ability and experience.
Recently, Perrault et al1 suggested a new 
approach of intrathoracic shunt quanti-
fication by using concomitantly thoracic 
bioimpedance (TB) and inert gas rebreathing 
(IGR). TB allows the determination of the 
systemic cardiac output ( Q̇s ) and IGR enables 
the assessment of the pulmonary blood flow 
( Q̇p ) such that the difference between  Q̇s  
measured by TB and  Q̇p  determined from 
the IGR measurement may be taken to reflect 
the intrathoracic shunt. The extent to which 
the use of these combined non-invasive tech-
niques provides quantification that is sensitive 
enough to be of use in the clinical manage-
ment of patients with intrathoracic shunts 
remains to be validated.
Isolated atrial septal defect (ASD) is a 
congenital heart disease leading to intracar-
diac left-to-right shunts of varying degrees 
depending on size of defect and left ventric-
ular compliance.2 Clinical management 
strengths and limitations of this study
 ► The validation of a double non-invasive approach for 
assessing the extent of cardiac shunt will provide an 
alternative to catheterisation.
 ► The double non-invasive approach is used concomi-
tantly to an arteriovenous catheterisation.
 ► The advantage of the bioimpedance method for 
stroke volume determination is that it is continuous 
and does not require patient participation.
 ► A limitation of inert gas rebreathing resides in the 
lack of control on patient rebreathing manoeuvres.
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generally entails assessment of  Q̇p/Q̇s  ratio since the clin-
ical decision for percutaneous closure is highly depen-
dent on the magnitude of the left-to-right shunt.3 4
The comparison of shunt quantification using the 
combined TB and IGR techniques with that obtained 
through routine measurements in isolated ASD provides 
an opportunity to validate the usefulness of this approach 
in clinical settings. The aim of this study is thus to vali-
date the combined non-invasive approach of  Q̇p/Q̇s  ratio 
measurement using TB and IGR in adults with secundum 
ASD by comparing results obtained with those from usual 
methods of Doppler echocardiography and direct Fick.
MEthods And AnAlysIs
setting
The present trial is a prospective, single-centre, observa-
tional, non-blinded study that compares the measurement 
of the pulmonary to systemic blood flow ratio ( Q̇p/Q̇s ) by 
the concomitant use of IGR and TB first to the non-in-
vasive Doppler echocardiography before and after defect 
closure and, second, to the direct Fick method during the 
defect closure procedure.
study objectives
The aim of the study is to validate the combined non-in-
vasive  Q̇p/Q̇s  ratio measurement in adults with ASD both 
before and after interventional closure in comparison to 
the Doppler echocardiography measure and during the 
closure procedure to the direct Fick method.
Methods
Methodology and design
The study will take place in the cardiology unit of the 
University Hospital Center, with the view to include 30 
patients over a period of 2 years from inclusion of first 
patient. Patients will be enrolled and followed by cardi-
ologists who will perform right heart catheterisation and 
Doppler echocardiography. The non-invasive measure-
ment of  ˙QpIGR/ ˙QsTB  using IGR and TB will be made 
before and after closure by trained clinical investigators 
without knowing the results obtained by cardiologists at 
the time of data acquisition.
Patients and public involvement
This research was designed by clinicians with the aim 
of simplifying patient’s management. Patients were not 
involved in the recruitment to or conduct of the study. 
According to the law in force in France, participants will 
be individually informed of the results at the end of the 
study.
Inclusion criteria
Patients with the following conditions will be included:
 ► Adult patients (≥18 years old) with confirmed 
secundum ASD with indication for interventional 
closure.5
 ► ASD regardless of the size, with suspicion of paradox-
ical embolism.
 ► Patients with significant intracardiac shunt (right 
ventricular volume overload) and pulmonary vascular 
resistance (PVR) <5 Wood units (WU).
 ► Patients with PVR ≥5 WU but <2/3 systemic vascular 
resistance or pulmonary arterial pressure <2/3 
systemic pressure and evidence of net left-to-right 
shunt ( Q̇p/Q̇s  >1.5).
Exclusion criteria
Patients will be excluded for the study if they present with 
one of the following criteria:
 ► Pregnant and breastfeeding women.
 ► Patient under assisted ventilation.
 ► Chronic respiratory disease ventilation/perfusion 
mismatch abnormalities.
 ► Complex congenital heart disease.
 ► Patients with coagulation function abnormalities.
 ► Patients who have not provided written consent.
 ► Patients in whom the use of TB or IGR is 
contraindicated.
Asd closure
Patients with secundum ASD eligible for percutaneous 
closure will be invited to participate in the study and to 
provide their signed informed consent. The percuta-
neous closure will be performed during a 3-day hospi-
talisation as per the usual institutional protocol. Resting 
haemodynamic measurements of shunt flow ( Q̇p/ ˙QsED
 ), systemic cardiac output ( Q̇s ) and right and left ventric-
ular functions will be performed using Doppler echo-
cardiography the day before as well as the day after 
percutaneous closure. Concomitantly, pulmonary blood 
flow by IGR ( ˙QpIGR ) and the systemic cardiac output 
by TB ( ˙QsTB ) will be measured. Right heart catheterisa-
tion will also be performed to directly measure  Q̇p  and 
 Q̇s  through a direct Fick computation ( Q̇p/ ˙QsFick ). An 
‘Amplatzer Septal Occluder (Saint Jude)’ will be used for 
ASD closure.
The sequence of procedures is shown in figure 1.
study group 
In this study, subjects serve as their own control for all 
relevant measures.
Approaches for cardiac output determination and shunt 
fraction quantification
Doppler echocardiography
Cardiac output measurement will be obtained using stan-
dard cardiac ultrasound (Ge-Vid S9, Philips-IE 33 and 
Philips-EPIC). Images will be captured in parasternal 
(short and long axes) and apical four-chamber views with 
2D cardiac ultrasound with patient in left lateral decu-
bitus. Cross-sectional area of the pulmonary annulus 
(Ap) and aortic annulus (Aa) will be measured.6 Velocity 
of blood will be assessed by pulsed Doppler. Velocity at 
the pulmonary annulus and aortic annulus is plotted on 
time to obtain the pulmonary and systemic velocity time 
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integral (VTIp and VTIa, respectively). Pulmonary and 
systemic cardiac output measurements are based on the 
following formulae.7
  Q̇p (mL · min−1) = HR (beats · min−1) × Ap (cm2) × VTIp (cm)  
  Q̇s (mL · min−1) = HR (beats · min−1) × Aa (cm2) × VTIa (cm)  
The echocardiographic shunt fraction is estimated 
from  Q̇p/Q̇s  ratio with values from three non-contin-
uous cardiac cycles being used for computation. In turn, 
the computed values will serve as reference for statistical 
analyses.8
Fick quantification of shunt
Under local anaesthesia and after pressure and ECG 
monitoring, a catheter will be inserted through the right 
femoral vein allowing blood gas samples at various sites 
and then pushed through the ASD for pulmonary vein 
sampling to enable oxygen saturation comparisons and 
left-to-right shunt contribution.
The standard Fick equation will be applied for compu-
tation of cardiac output to include or exclude shunted 
blood fractions.
Systemic cardiac output will be taken as:
  
˙QsFick (mL · min
−1) = V̇O2 (mL · min
−1)/[CaO2 − C−
v
O2(mL · min
−1)]
  where
 ̇VO2 =whole body oxygen consumption.
 CaO2 = arterial oxygen content in the femoral artery.
 C−v O2 =mixed venous oxygen content obtained from 
the oxygen saturation and haemoglobin concentra-
tion in inferior vena cava (IVC) and superior vena cava 
(SVC) especially for patients with ASD.9
Shunt contribution will be obtained through a series of 
Fick computations using successive venous content values 
of samples in the IVC, the SVC, the innominate vein, the 
right atrium and ventricle and the pulmonary artery.
The oxygen content measured at each of these sites will 
be introduced into the Fick equation to determine the 
corresponding cardiac output, reflecting the absence or 
presence of blood shunt contribution.
Double non-invasive cardiac output measurement
This approach will be based on the use of two cardiac 
output determination methods simultaneously, leading 
to intrathoracic shunt quantification: TB measurement 
reflects  Q̇s  while IGR reflects  Q̇p  (figure 2).
Thoracic bioimpedance
The methodology of PhysioFlow (Manatec, France) 
has been well described in the study of Charloux et al.10 
TB was validated against the Fick method in healthy 
subjects11 and in patients with chronic heart and respira-
tory diseases.10 12–14 Two sets of cutaneous electrodes are 
placed on the thorax of the subject to reflect changes in 
bioimpedance. The changes in thoracic impedance (ΔZ) 
occurring as a result of cardiac ejection are continuously 
recorded and reflect the stroke volume (SV). Systemic 
cardiac output is then determined from the multiplica-
tion of SV and heart rate. The  ˙QsTB  value is obtained as 
the average of continuous data over the last 30 s (approx-
imately 25–30 heartbeats) immediately prior to the 
rebreathing manoeuvres.
Inert gas rebreathing
IGR is validated against invasive method Fick and ther-
modilution for cardiac output measurement in both 
healthy subjects and patients with heart disease.15–18 The 
Innocor (Innovision, Odense, Denmark) device, which 
will be used in this study, measures the  ˙QpIGR  using the 
rebreathing technique with a mixture of gases (sulfur 
hexafluoride (SF6), nitrous oxide (N2O) and oxygen 
Figure 1 Consort diagram: flow chart. Patients indicated to ASD percutaneous closure will be proposed to the study. Three 
assessments of the ratio with the concomitant use of IGR and TB are planned during a 3-days hospitalization: the day before 
and after intervention in comparison to the Doppler Cardiac Ultrasound measure and one the day of intervention in comparison 
to the direct Fick method. ASD: atrial septal defect.  
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(O2)). SF6 is an insoluble inert gas which is used as a 
marker of gas mixture distribution homogeneity. N2O is 
a blood soluble gas which serves as gas tracer. Its disap-
pearance from the lung is proportional to the rate of 
pulmonary blood flow.19 20 Rebreathing procedures will 
be achieved at a breathing rate of 20/min, each separated 
by 3 min. Each rebreathing manoeuvre will last 15–20 s 
which represents a total of 25–30 cardiac cycles and will 
result in a cardiac output value. The average of the three 
cardiac output measurements will be used as mean for 
statistical analyses.
Under normal physiological conditions,  Q̇p  is equiv-
alent to  Q̇s . The absolute difference between  ˙QsTB  and 
 ˙QpIGR  quantifies the intrathoracic shunt. The qualitative 
aspect of the intrathoracic shunt with a shunt fraction 
ratio such that  Q̇p/Q̇s  ratio >1.0 reflects a left-to-right 
shunt. The severity of the shunt is expressed by the value 
of the  Q̇p/Q̇s  ratio, such that higher shunt ratios reflect 
greater severity.
study outcomes
Primary outcome
The main outcome of the study is the difference between 
 Q̇p/Q̇s  ratio measured by the double non-invasive tech-
nique ( ˙QpIGR/ ˙QsTB ) when compared with the Doppler 
echocardiography  Q̇p/Q̇s  ratio taken before interven-
tional closure of secundum ASD. The working hypothesis 
is that there will be no significant difference between 
these ratios.
Secondary outcomes
The secondary outcomes are:
The  Q̇p/Q̇s  ratio measured by the double non-invasive 
technique ( ˙QpIGR/ ˙QsTB ) in comparison to the inva-
sive direct Fick method.
The  Q̇p/Q̇s  ratio measurements obtained after 
ASD closure by the double non-invasive technique 
( ˙QpIGR/ ˙QsTB ) to those measured using Doppler echo-
cardiography ( Q̇p/ ˙QsED2 ).
Relationship between extent of shunt  ˙QpIGR/ ˙QsTB  
assessed by Fick, echocardiography and double ap-
proach and cardiac output measurements.
study limitations
The study presents some methodological limitations:
First, there is a lack of control on patient rebreathing 
manoeuvre with the IGR. Second, some patient’s factors 
such as preload or anxiety might influence physiological 
left-to-right shunt volumes before, during or after cathe-
terisation to varying degrees. This bias becomes irrelevant 
after shunt closure, if shunt closure is completed. Third, 
the difference of time periods of data acquisition between 
the methods of cardiac output measurement (lower 
number of heart cycles captured by echocardiography, as 
compared with the other monitoring methods averaging 
more heart and respiratory cycles) might introduce a bias 
in shunt determination.
statistical considerations
Estimation of sample size
To evaluate the agreement between the double non-inva-
sive approach and the gold standard technique, a sample 
size of 30 subjects would provide a power of 90% to high-
light an agreement of 0.8 (Lin’s concordance coefficient) 
for a two-sided type I error at 5%. A sequential explor-
atory analysis will be proposed each 10 patients without 
correction of type I error.
Statistical analysis
All statistical analyses will be performed using Stata soft-
ware (V.13, StataCorp, College Station, USA). A two-sided 
type I error will be set at 0.05 to indicate statistical signif-
icance. Continuous data will be presented as mean±SD 
or as median (IQR), according to the statistical distri-
bution. The assumption of normality will be studied 
with the Shapiro-Wilk test. The primary analysis will be 
performed using correlation coefficient (Pearson or 
Spearman according to the statistical distribution), Lin’s 
concordance coefficient and Bland and Altman plot in 
order to study the accuracy between non-invasive  Q̇p/Q̇s  
measurement and Doppler echocardiography in adults 
with ASD. The correlation and concordance coefficients 
will be presented with 95% CIs. 
Figure 2 Illustration of the thoracic cardiovascular 
circulation in Atrial septal defect (arrow). The blue frame 
represents the pulmonary circulation measured with the 
IGR (Innocor®) and the red frame the systemic circulation 
measured with the TB (Physioflow®). 1. Right side of the 
heart; 2. Vena cava; 3. Pulmonary artery; 4. Trachea; 5. Lung; 
6. Pulmonary Veins; 7. Left side of the heart; 8. Aorta. 
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Secondary analysis
In addition, the  Q̇p/Q̇s  obtained using each method will 
be examined regardless of the size of ASD using correla-
tion coefficient and analysis of variance (ANOVA) or 
Kruskal-Wallis test (if the assumptions of ANOVA are not 
met: normality and homoscedasticity studied by Bartlett 
test). The same statistical analyses will be carried out with 
respect to direct Fick measured shunt ratios. Finally, the 
intraindividual and interindividual reproducibility of 
the double non-invasive approach will be evaluated by 
intraclass correlation coefficient (ICC estimated from 
a mixed model with patient as random effect). ICC will 
be presented with a 95% CI.
EthICs And dIssEMInAtIon
Approval
According to the French regulation on clinical trials, the 
study has been submitted to the ‘Comité de Protection 
des Personnes Ouest V’ (Reference 2017-A03149-44) and 
to the ‘Agence Nationale de Sécurité du Medicament 
(ANSM)’ (the French regulatory authority for research). 
Approval from the Ethics Review Board is dated 13 
February 2018 and from the ANSM 30 January 2018. Any 
modification in the protocol or informed consent during 
the study will be presented to the reference authority. 
The study is currently registered on the clinical website 
under the number NCT03437148.
Patient informed consent
All patients will receive verbal and written information on 
the aim of the study and the protocol. Written informed 
consent will be obtained prior to their participation in the 
study. During the study, the patients will have the possi-
bility to ask all questions concerning the protocol from 
the cardiologist or investigator. They will be informed 
that they are free to stop the study at any time at their 
own discretion.
data collection and quality management
Data will be collected by the principal investigator and the 
trained clinical research assistant. Data will be registered 
in written notebooks at each assessment point for each 
patient. Data capture will be achieved using Research 
Electronic Data Capture. A clinical research assistant will 
be commissioned to ensure the progress of the study, 
and the data capture according to the standard operating 
procedures implemented at the University Hospital of 
Clermont-Ferrand in accordance with the Good Clinical 
Practice in current French laws.
Access to data
The data set will be the property of the institution. 
However, the principal investigator and the project 
manager will have full access to the final data set. The 
results will be communicated in a peer-reviewed journal, 
will be presented at an international conference and will 
appear in  ClinicalTrials. gov.
dIsCussIon
To the best of our knowledge, our study is the first to assess 
the  Q̇p/Q̇s  ratio using a combined non-invasive approach 
of  Q̇p/Q̇s  ratio measurement using TB and IGR.
Cardiac output is a valuable physiological measure-
ment to provide insight into integrated cardiocirculatory 
systemic functions at play to refine diagnosis and capa-
bility for several chronic disease states.18 To date, accu-
rate measurement of cardiac output remains challenging 
in everyday clinical environments. Over the last decade, 
TB has been introduced which provides an interesting 
alternative as it allows to monitor values of continuous 
periods.10 11 This approach, however, may be limiting 
with respect to identifying right and left heart contri-
butions. Rebreathing methodologies for cardiac output 
determinations provide such an opportunity. Peyton et al 
demonstrated the value of IGR to calculate the ratio Qp/
Qs by combining the shunt equation and Fick principle. 
The limits of their approach stand in the impossibility to 
extend the application to intracardiac shunt.21
The aim of this study is to demonstrate the non-in-
feriority of the combined non-invasive approach of 
 Q̇p/Q̇s  ratio measurement using TB and IGR in adults 
with secundum ASD by comparing the results obtained 
with those from usual methods (Doppler echocardiog-
raphy and direct Fick). In this context, Perrault et al1 
used TB and IGR simultaneously to measure the cardiac 
output either by TB, IGR or CO2 rebreathing (with or 
without correction by PaCO2) in patients with chronic 
obstructive pulmonary disease at rest and exercise. The 
ability of TB and IGR to correctively measure Qs and Qp, 
respectively, was confirmed. Interesting results lie on the 
possibility to estimate the shunt effect due to underesti-
mation of cardiac output by IGR in comparison to TB.
The added value of the double non-invasive approach 
lies in the possibility to quantify and qualify the intratho-
racic shunt from physiological haemodynamic parame-
ters with relatively minor discomfort to the patient. The 
simultaneous use of IGR and TB is non-operator depen-
dent, totally non-invasive and easy to use contrary to the 
Doppler echocardiography or the Fick methodology. In 
addition, the combined technique can be successfully 
used during clinical cardiopulmonary exercise testing 
enabling early or refined diagnoses or for follow-up and 
clinical management.5 22 23 Such an approach enables to 
quantify or qualify the shunt on exercise or shunt reversal 
and cyanosis which may first appear under exercise.24
Thus, the first step of this process is to evaluate the 
concomitant use of TB and IGR at rest in intracardiac 
shunt in comparison to standard methods.
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